Ott E, Nussmeier NA, Duke PC 2003 Efficacy and safety of the cyclo-oxygenase 2 inhibitors parecoxib and valdecoxib
in patients undergoing coronary bypass surgery Journal of Thoracic and Cardiovascular Surgery 125 1481-1492
, a cyclooxygenase-2-specific inhibitor, is effective in treating primary dysmenorrhea.
However, in the years since the voluntary withdrawal of rofecoxib and valdecoxib
from the market, few practitioners aside from rheumatologists prescribe selective COX-2 NSAIDs for children, according to survey results.
Based on increasing reports of thrombotic events associated with rofecoxib, celecoxib, and valdecoxib
, the Food and Drug Administration (FDA) issued a health advisory on December 23, 2004, concerning the use of all COXIBs.
Presurgical intravenous parecoxib sodium and follow-up oral valdecoxib
for pain management after laparoscopic cholecystectomy surgery reduces opioid requirements and opioid-related adverse effects.
Complications of the COX-2 inhibitors parecoxib and valdecoxib
after cardiac surgery.
Efficacy and tolerability of valdecoxib
in treating the signs and symptoms of severe rheumatoid arthritis: a 12-week multicenter randomized double-blind placebo-controlled study.
In addition, the off-label promotion of the arthritis drug valdecoxib
(Bextra), the epilepsy drug gabapentin (Neurontin), and the schizophrenia drug olanzapine (Zyprexa) resulted in criminal prosecutions, fines and settlements of hundreds of millions of dollars, and a record-setting settlement of US$2.3 billion in the case of valdecoxib
(see Gardiner Harris, "Pfizer Pays $2.3 Billion to Settle Marketing Case", The New York Times (2 September 2009), online: The New York Times <www.nytimes.com>).
Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib
and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
(3) The findings of this meeting led to the withdrawal of valdecoxib
from the market and labeling changes for prescription and nonprescription NSAIDs regarding increased risk of CV events and gastrointestinal (GI) bleeding.
Remote NSAID Exposure Indomethacin 1.71 Sulindac 1.41 Meloxicam 1.37 Rofecoxib 1.32 Piroxicam 1.18 Ibuprofen 1.11 Celecoxib 1.09 Naproxen 1.08 Valdecoxib
0.99 Nabumetone 0.83 Source: Dr.
* COX-2 specific inhibitors (cyclooxygenase inhibitors), are a fairly new class of NSAIDs that include celecoxib (Celebrex), valdecoxib
(Bextra) and mobic (Meloxicam).